search
Back to results

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Primary Purpose

Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Axitinib
Crizotinib
Palbociclib Isethionate
Talazoparib Tosylate
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Malignant Solid Neoplasm

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Pathogenic or likely pathogenic germline or somatic gene defect as determined by local assessment and classification in at least one of the following:

    • Defect in DNA damage response (DDR) genes such as: BRCA1/2, PALB2, RAD51C/D, or other related genes at the discretion of the principal investigator in consultation with the MD Anderson Cancer Center Institute for Personalized Cancer Therapy Precision Oncology Decision Support (PODS) group (Arms A-C)
    • Defect in MET, ALK or ROS1, e.g. MET mutations or amplifications, high MET expression, ALK translocations, ROS1 translocations (eligible for Arm C: talazoparib + crizotinib)
    • NOTE: Patients with metastatic castration-resistant prostate cancer can enroll in Arm B with talazoparib + axitinib without a specific and/or selected mutation
    • Patients who are eligible for more than one Arm will be assigned according to physician preference
  • Histological or cytological diagnosis of a solid tumor that is advanced/metastatic, intolerable to standard therapy, resistant to effective standard therapy, or for which no standard therapy is available
  • Availability of a fresh or recent tumor tissue sample from a diagnostic biopsy/surgery or a metastatic tumor biopsy; the sample must have been obtained within 12 months prior to study enrollment. When only bone disease is present, an archival tumor tissue sample obtained within 5 years prior to study enrollment may be accepted for non-prostate cancer patients and a fresh bone biopsy may be accepted for prostate cancer patients only NOTE: A fresh biopsy should be encouraged for all patients at time of enrollment even if a previous biopsy is available. Optional on-treatment and at-progression biopsies will be encouraged for all patients
  • Have measurable disease at study enrollment as defined by RECIST v1.1 with at least 1 measurable lesion that has not previously been irradiated; or patients may have bone metastatic disease evaluable by Prostate Cancer Working Group 2 (PCWG2) for subjects with metastatic castration-resistant prostate cancer (mCRPC), or according to the tumor evaluation criteria best suited and accepted for the tumor type being evaluated)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1
  • Absolute Neutrophil Count (ANC) >= 1,500/mm^3 or >= 1.5 x 10^9/L (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment)
  • Platelets >= 100,000/mm^3 or >= 100 x 10^9/L (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment)
  • Hemoglobin >= 9 g/dL (>= 5.6 mmol/L) (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment)
  • estimated creatinine clearance >= 60 mL/min will be required during dose-escalation phase, according to the Cockcroft-Gault formula

    • Where creatinine clearance (CLCR) (creatinine clearance) is measured in mL/min, age is expressed in years, weight in kilograms (kg), and SCR (serum creatinine) in mg/dL
    • Or as measured by 24h urine assessment NOTE: Patients with moderate renal impairment (30-59 mL/min) will be considered during the dose expansion phase. A reduced starting dose for talazoparib will be considered in these patients
  • Total serum bilirubin =< 1.5 x the upper limit of normal range (ULN)
  • Aspartate and Alanine aminotransferase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) =< 5 x ULN
  • Female Patients of childbearing potential must have negative serum pregnancy or urine pregnancy test at screening. Female patients of non-childbearing potential must meet at least one of the following criteria:

    • Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state
    • Have undergone a documented hysterectomy and/or bilateral oophorectomy
    • Have medically confirmed ovarian failure All other female patients are considered to be of childbearing potential
  • Evidence of a personally signed and dated informed consent document, within > 28 days prior to enrollment, indicating that the patient has been informed of all pertinent aspects of the study
  • Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
  • Able to swallow the study drug, have no known intolerance to study drugs or excipients, and comply with study requirements

Exclusion Criteria:

  • Prior anti-cancer therapy within 2 weeks prior to study enrollment or prior radiation therapy within 2 weeks prior to study enrollment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed at least 2 days prior to study enrollment and no clinically significant toxicities are expected (e.g. mucositis, esophagitis)
  • Major surgery within 4 weeks prior to study enrollment
  • Patients with known hypersensitivity to either talazoparib or the additional study drug to be received per treatment arm: palbociclib (Arm A), axitinib (Arm B), crizotinib (Arm C)
  • Diagnosis of myelodysplastic syndrome (MDS)
  • Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 2 weeks, and are neurologically stable. Of note, patients who required a single dose of corticosteroids on days receiving radiation treatment do not require a 2-week washout
  • Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation
  • Persisting toxicity related to prior therapy (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0 Grade > 1). However, alopecia and sensory neuropathy Grade =< 2, or other Grade =< 2 adverse events not constituting a safety risk, based on the investigator's judgement, are acceptable
  • Active infection requiring systemic therapy. Minor infections, e.g. periodontal infection or urinary tract infection (UTI), which may be treated with short term oral antibiotics are allowed
  • Patients with known uncontrolled human immunodeficiency virus (HIV) virus or acquired immunodeficiency syndrome. Note: Patients with history of controlled HIV virus will be considered eligible for this trial
  • Patients with uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening. Note: Patients with controlled hepatitis B or hepatitis C will be considered eligible for this trial
  • Clinically significant cardiovascular disease, including any of the following:

    • Myocardial infarction or symptomatic cardiac ischemia within 6 months before screening
    • Congestive heart failure New York Heart Association class III or IV
    • History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes) within 1 year before screening
    • History of Mobitz II second degree or third degree heart block unless a permanent pacemaker is in place
    • Hypotension as indicated by systolic blood pressure < 86 mm Hg at screening
    • Bradycardia as indicated by a heart rate of <45 beats per minute on the screening electrocardiogram
    • Uncontrolled hypertension as indicated by systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening
  • Current use of potent P-gp inhibitors within 7 days prior to enrollment: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil.

    • NOTE: Patients who have recently been on enzalutamide require a 28 day washout period due to longer elimination half-life of this therapy
  • Patients treated within the last 7 days prior to enrollment with:

    • Food or drugs that are known to be strong CYP (cytochrome P-450) 3A4 inhibitors (ie, amprenavir, atazanavir, boceprevir, clarithromycin, conivaptan, delavirdine, diltiazem, erythromycin, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, voriconazole, and grapefruit or grapefruit juice). Drugs that are known to be strong CYP3A4 inducers (ie, carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John's wort
  • Inability to swallow capsules, known malabsorption syndrome, or other conditions that may impair absorption of study drugs
  • Bisphosphonate or denosumab dosage that was not stable (i.e. not the same) for at least 2 weeks before study enrollment for patients receiving these therapies
  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the patient inappropriate for entry into this study
  • Medical, psychological, or social conditions that may interfere with the patient's participation in the study, or with the evaluation of the study results
  • Diagnosis of any other malignancy within 2 years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast, bladder, or cervix, or low grade (Gleason =< 6) prostate cancer on surveillance without any plans for treatment intervention (e.g. surgery, radiation, or castration), or other early-stage low risk cancers
  • Pregnant female patients; breastfeeding female patients; fertile male patients; and female patients of childbearing potential who are unwilling or unable to use 2 methods of contraception for the duration of the study and for at least 7 months after the last dose of study drugs for female patients or 4 months after the last dose of study drugs for male patients, whichever is later for the individual patient. Male patients are prohibited from sperm donation while enrolled in this study and for 4 months after the last dose of the study drugs. Highly effective methods of contraception are those that alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly. These methods include:

    • Established use of oral, inserted, or injected or implanted hormonal methods of contraception are allowed provided the patient remains on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness
    • Correctly placed copper containing intrauterine device (IUD)
    • Male condom or female condom used with spermicide (i.e. foam, gel, film, cream or suppository)
    • Male sterilization with appropriately confirmed absence of sperm in the postvasectomy ejaculate
    • Bilateral tubal ligation or bilateral oophorectomy

Sites / Locations

  • M D Anderson Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Arm I (talazoparib, palbociclib)

Arm II (talazoparib, axitinib)

Arm III (talazoparib, crizotinib)

Arm Description

Patients receive talazoparib PO QD on days 1-21 or 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.

Patients receive talazoparib PO QD on days 1-28 and axitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.

Patients receive talazoparib PO QD on days 1-28 and crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.

Outcomes

Primary Outcome Measures

Incidence of adverse events
Incidence and severity of adverse events and serious adverse events in patients being treated with the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C). Severity of adverse events (AEs) will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Tabulations will be produced for safety parameters.
Incidence of dose limiting toxicities
Incidence of dose limiting toxicities of the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C) will be assessed. Severity of AEs will be graded according to the NCI CTCAE version 5.0.

Secondary Outcome Measures

Plasma pharmacokinetic (PK) parameters (maximum plasma concentration)
Plasma pharmacokinetic parameters including the maximum plasma concentration. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Furthermore, maximum and trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Plasma pharmacokinetic (PK) parameters (time to maximum plasma concentration)
Plasma pharmacokinetic parameters including the time to maximum plasma concentration Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Furthermore, maximum and trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Plasma pharmacokinetic (PK) parameters (area under the plasma concentration)
Plasma pharmacokinetic parameters including the area under the plasma concentration versus time curve will be estimated using non-compartmental analysis. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Furthermore, maximum and trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Plasma pharmacokinetic parameters (Ctrough)
Plasma pharmacokinetic parameters including the Ctrough. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Plasma pharmacokinetic parameters (maximum)
Plasma pharmacokinetic parameters including the maximum. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Maximum serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Clinical benefit rate
Will assess antitumor activity by clinical benefit rate complete response (CR) + partial response (PR) + stable disease > 4 months per Response Evaluation Criteria in Solid Tumors (RECIST) version(v) 1.1.
Duration of response
Estimated using Kaplan-Meier methods. A 95% confidence interval of response rate will be estimated based on the binomial distribution.
Objective response
Objective response is defined as a best overall response of CR or PR per RECIST v1.1.
Progression free survival
Estimated using Kaplan-Meier methods. A 95% confidence interval of response rate will be estimated based on the binomial distribution.
Overall survival
Estimated using Kaplan-Meier methods. A 95% confidence interval of response rate will be estimated based on the binomial distribution.

Full Information

First Posted
December 28, 2020
Last Updated
September 30, 2023
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT04693468
Brief Title
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
Official Title
Modular Phase 1B Hypothesis-Testing, Biomarker-Driven, Talazoparib Combination Trial (TalaCom)
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
September 3, 2025 (Anticipated)
Study Completion Date
September 3, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This phase Ib trial is to find out the best dose, possible benefits and/or side effects of talazoparib when given in combination with palbociclib, axitinib, or crizotinib in treating patients with solid tumors that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). PARPs are proteins that help repair damaged DNA, the genetic material that serves as the body's instruction book. PARP inhibitors, such as talazoparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Palbociclib, axitinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving talazoparib in combination with palbociclib, axitinib, or crizotinib may help control locally advanced or metastatic solid tumors.
Detailed Description
PRIMARY OBJECTIVES: I. To determine the safety and tolerability, and establish the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of the combination of talazoparib tosylate (talazoparib) with palbociclib isethionate (palbociclib) (Arm A), axitinib (Arm B), and crizotinib (Arm C) in patients with advanced solid tumors. II. To assess the safety and toxicity profile of the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C). SECONDARY OBJECTIVES: I. To evaluate the pharmacokinetic and pharmacodynamic profile of the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C). II. To obtain a preliminary assessment of the antitumor activity of the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C). III. To assess predictive biomarkers of response and resistance to the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C). OUTLINE: This is a phase I, dose-escalation study. Patients are assigned to 1 of 3 arms. ARM A: Patients receive talazoparib orally (PO) once daily (QD) on days 1-21 or 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion. ARM B: Patients receive talazoparib PO QD on days 1-28 and axitinib PO twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion. ARM C: Patients receive talazoparib PO QD on days 1-28 and crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion. After the completion of study treatment, patients are followed up for 90 days and then every 12 weeks until progression of disease, receipt of another cancer drug, or for another two years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
111 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm I (talazoparib, palbociclib)
Arm Type
Experimental
Arm Description
Patients receive talazoparib PO QD on days 1-21 or 1-28 and palbociclib PO QD on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
Arm Title
Arm II (talazoparib, axitinib)
Arm Type
Experimental
Arm Description
Patients receive talazoparib PO QD on days 1-28 and axitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
Arm Title
Arm III (talazoparib, crizotinib)
Arm Type
Experimental
Arm Description
Patients receive talazoparib PO QD on days 1-28 and crizotinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
Intervention Type
Drug
Intervention Name(s)
Axitinib
Other Intervention Name(s)
AG-013736, AG013736, Inlyta
Intervention Description
Given PO
Intervention Type
Drug
Intervention Name(s)
Crizotinib
Other Intervention Name(s)
MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, Xalkori
Intervention Description
Given PO
Intervention Type
Drug
Intervention Name(s)
Palbociclib Isethionate
Other Intervention Name(s)
PD 0332991-0054, PF-00080665-73
Intervention Description
Given PO
Intervention Type
Drug
Intervention Name(s)
Talazoparib Tosylate
Other Intervention Name(s)
Talzenna
Intervention Description
Given PO
Primary Outcome Measure Information:
Title
Incidence of adverse events
Description
Incidence and severity of adverse events and serious adverse events in patients being treated with the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C). Severity of adverse events (AEs) will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Tabulations will be produced for safety parameters.
Time Frame
Up to 30 days after the last investigational product administration
Title
Incidence of dose limiting toxicities
Description
Incidence of dose limiting toxicities of the combination of talazoparib with palbociclib (Arm A), axitinib (Arm B), and crizotinib (Arm C) will be assessed. Severity of AEs will be graded according to the NCI CTCAE version 5.0.
Time Frame
Up to 30 days after the last investigational product administration
Secondary Outcome Measure Information:
Title
Plasma pharmacokinetic (PK) parameters (maximum plasma concentration)
Description
Plasma pharmacokinetic parameters including the maximum plasma concentration. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Furthermore, maximum and trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Time Frame
Up to 2 years
Title
Plasma pharmacokinetic (PK) parameters (time to maximum plasma concentration)
Description
Plasma pharmacokinetic parameters including the time to maximum plasma concentration Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Furthermore, maximum and trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Time Frame
Up to 2 years
Title
Plasma pharmacokinetic (PK) parameters (area under the plasma concentration)
Description
Plasma pharmacokinetic parameters including the area under the plasma concentration versus time curve will be estimated using non-compartmental analysis. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Furthermore, maximum and trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Time Frame
Up to 2 years
Title
Plasma pharmacokinetic parameters (Ctrough)
Description
Plasma pharmacokinetic parameters including the Ctrough. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Trough serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Time Frame
Up to 2 years
Title
Plasma pharmacokinetic parameters (maximum)
Description
Plasma pharmacokinetic parameters including the maximum. Descriptive statistics will be provided for these PK parameters in tabular form (n, mean, SD, CV, median, minimum, maximum, geometric mean and its associated CV) by trial arm, dose, cycle and day. Individual curves of serum concentration of each study drug versus time will be presented on log- and linear scale for all patients in the PK population. Maximum serum concentrations for the period from first dose to end of treatment will be presented on linear scale individual plots.
Time Frame
Up to 2 years
Title
Clinical benefit rate
Description
Will assess antitumor activity by clinical benefit rate complete response (CR) + partial response (PR) + stable disease > 4 months per Response Evaluation Criteria in Solid Tumors (RECIST) version(v) 1.1.
Time Frame
Up to 2 years
Title
Duration of response
Description
Estimated using Kaplan-Meier methods. A 95% confidence interval of response rate will be estimated based on the binomial distribution.
Time Frame
Up to 2 years
Title
Objective response
Description
Objective response is defined as a best overall response of CR or PR per RECIST v1.1.
Time Frame
Up to 2 years
Title
Progression free survival
Description
Estimated using Kaplan-Meier methods. A 95% confidence interval of response rate will be estimated based on the binomial distribution.
Time Frame
Up to 2 years
Title
Overall survival
Description
Estimated using Kaplan-Meier methods. A 95% confidence interval of response rate will be estimated based on the binomial distribution.
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pathogenic or likely pathogenic germline or somatic gene defect as determined by local assessment and classification in at least one of the following: Defect in DNA damage response (DDR) genes such as: BRCA1/2, PALB2, RAD51C/D, or other related genes at the discretion of the principal investigator in consultation with the MD Anderson Cancer Center Institute for Personalized Cancer Therapy Precision Oncology Decision Support (PODS) group (Arms A-C) Defect in MET, ALK or ROS1, e.g. MET mutations or amplifications, high MET expression, ALK translocations, ROS1 translocations (eligible for Arm C: talazoparib + crizotinib) NOTE: Patients with metastatic castration-resistant prostate cancer can enroll in Arm B with talazoparib + axitinib without a specific and/or selected mutation Patients who are eligible for more than one Arm will be assigned according to physician preference Histological or cytological diagnosis of a solid tumor that is advanced/metastatic, intolerable to standard therapy, resistant to effective standard therapy, or for which no standard therapy is available Availability of a fresh or recent tumor tissue sample from a diagnostic biopsy/surgery or a metastatic tumor biopsy; the sample must have been obtained within 12 months prior to study enrollment. When only bone disease is present, an archival tumor tissue sample obtained within 5 years prior to study enrollment may be accepted for non-prostate cancer patients and a fresh bone biopsy may be accepted for prostate cancer patients only NOTE: A fresh biopsy should be encouraged for all patients at time of enrollment even if a previous biopsy is available. Optional on-treatment and at-progression biopsies will be encouraged for all patients Have measurable disease at study enrollment as defined by RECIST v1.1 with at least 1 measurable lesion that has not previously been irradiated; or patients may have bone metastatic disease evaluable by Prostate Cancer Working Group 2 (PCWG2) for subjects with metastatic castration-resistant prostate cancer (mCRPC), or according to the tumor evaluation criteria best suited and accepted for the tumor type being evaluated) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 1 Absolute Neutrophil Count (ANC) >= 1,500/mm^3 or >= 1.5 x 10^9/L (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment) Platelets >= 100,000/mm^3 or >= 100 x 10^9/L (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment) Hemoglobin >= 9 g/dL (>= 5.6 mmol/L) (without hematopoietic growth factor or transfusion support within 14 days prior to study enrollment) estimated creatinine clearance >= 60 mL/min will be required during dose-escalation phase, according to the Cockcroft-Gault formula Where creatinine clearance (CLCR) (creatinine clearance) is measured in mL/min, age is expressed in years, weight in kilograms (kg), and SCR (serum creatinine) in mg/dL Or as measured by 24h urine assessment NOTE: Patients with moderate renal impairment (30-59 mL/min) will be considered during the dose expansion phase. A reduced starting dose for talazoparib will be considered in these patients Total serum bilirubin =< 1.5 x the upper limit of normal range (ULN) Aspartate and Alanine aminotransferase (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) =< 5 x ULN Female Patients of childbearing potential must have negative serum pregnancy or urine pregnancy test at screening. Female patients of non-childbearing potential must meet at least one of the following criteria: Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause and have a serum follicle-stimulating hormone (FSH) level confirming the postmenopausal state Have undergone a documented hysterectomy and/or bilateral oophorectomy Have medically confirmed ovarian failure All other female patients are considered to be of childbearing potential Evidence of a personally signed and dated informed consent document, within > 28 days prior to enrollment, indicating that the patient has been informed of all pertinent aspects of the study Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures Able to swallow the study drug, have no known intolerance to study drugs or excipients, and comply with study requirements Exclusion Criteria: Prior anti-cancer therapy within 2 weeks prior to study enrollment or prior radiation therapy within 2 weeks prior to study enrollment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed at least 2 days prior to study enrollment and no clinically significant toxicities are expected (e.g. mucositis, esophagitis) Major surgery within 4 weeks prior to study enrollment Patients with known hypersensitivity to either talazoparib or the additional study drug to be received per treatment arm: palbociclib (Arm A), axitinib (Arm B), crizotinib (Arm C) Diagnosis of myelodysplastic syndrome (MDS) Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 2 weeks, and are neurologically stable. Of note, patients who required a single dose of corticosteroids on days receiving radiation treatment do not require a 2-week washout Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation Persisting toxicity related to prior therapy (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0 Grade > 1). However, alopecia and sensory neuropathy Grade =< 2, or other Grade =< 2 adverse events not constituting a safety risk, based on the investigator's judgement, are acceptable Active infection requiring systemic therapy. Minor infections, e.g. periodontal infection or urinary tract infection (UTI), which may be treated with short term oral antibiotics are allowed Patients with known uncontrolled human immunodeficiency virus (HIV) virus or acquired immunodeficiency syndrome. Note: Patients with history of controlled HIV virus will be considered eligible for this trial Patients with uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening. Note: Patients with controlled hepatitis B or hepatitis C will be considered eligible for this trial Clinically significant cardiovascular disease, including any of the following: Myocardial infarction or symptomatic cardiac ischemia within 6 months before screening Congestive heart failure New York Heart Association class III or IV History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes) within 1 year before screening History of Mobitz II second degree or third degree heart block unless a permanent pacemaker is in place Hypotension as indicated by systolic blood pressure < 86 mm Hg at screening Bradycardia as indicated by a heart rate of <45 beats per minute on the screening electrocardiogram Uncontrolled hypertension as indicated by systolic blood pressure > 170 mm Hg or diastolic blood pressure > 105 mm Hg at screening Current use of potent P-gp inhibitors within 7 days prior to enrollment: amiodarone, carvedilol, clarithromycin, cobicistat, dronedarone, erythromycin, glecaprevir/pibrentasvir, indinavir, itraconazole, ketoconazole, lapatinib, lopinavir, propafenone, quinidine, ranolazine, ritonavir, saquinavir, sofosbuvir/velpatasvir/voxilaprevir, telaprevir, tipranavir, valspodar, and verapamil. NOTE: Patients who have recently been on enzalutamide require a 28 day washout period due to longer elimination half-life of this therapy Patients treated within the last 7 days prior to enrollment with: Food or drugs that are known to be strong CYP (cytochrome P-450) 3A4 inhibitors (ie, amprenavir, atazanavir, boceprevir, clarithromycin, conivaptan, delavirdine, diltiazem, erythromycin, fosamprenavir, indinavir, itraconazole, ketoconazole, lopinavir, mibefradil, miconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, voriconazole, and grapefruit or grapefruit juice). Drugs that are known to be strong CYP3A4 inducers (ie, carbamazepine, felbamate, nevirapine, phenobarbital, phenytoin, primidone, rifabutin, rifampin, rifapentin, and St. John's wort Inability to swallow capsules, known malabsorption syndrome, or other conditions that may impair absorption of study drugs Bisphosphonate or denosumab dosage that was not stable (i.e. not the same) for at least 2 weeks before study enrollment for patients receiving these therapies Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the patient inappropriate for entry into this study Medical, psychological, or social conditions that may interfere with the patient's participation in the study, or with the evaluation of the study results Diagnosis of any other malignancy within 2 years prior to study enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast, bladder, or cervix, or low grade (Gleason =< 6) prostate cancer on surveillance without any plans for treatment intervention (e.g. surgery, radiation, or castration), or other early-stage low risk cancers Pregnant female patients; breastfeeding female patients; fertile male patients; and female patients of childbearing potential who are unwilling or unable to use 2 methods of contraception for the duration of the study and for at least 7 months after the last dose of study drugs for female patients or 4 months after the last dose of study drugs for male patients, whichever is later for the individual patient. Male patients are prohibited from sperm donation while enrolled in this study and for 4 months after the last dose of the study drugs. Highly effective methods of contraception are those that alone or in combination, result in a failure rate of less than 1% per year when used consistently and correctly. These methods include: Established use of oral, inserted, or injected or implanted hormonal methods of contraception are allowed provided the patient remains on the same treatment throughout the entire study and has been using that hormonal contraceptive for an adequate period of time to ensure effectiveness Correctly placed copper containing intrauterine device (IUD) Male condom or female condom used with spermicide (i.e. foam, gel, film, cream or suppository) Male sterilization with appropriately confirmed absence of sperm in the postvasectomy ejaculate Bilateral tubal ligation or bilateral oophorectomy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Timothy A. Yap
Phone
713-563-1784
Email
tyap@mdanderson.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timothy A Yap
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
M D Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Timothy A. Yap
Phone
713-563-1784
Email
tyap@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Timothy A. Yap

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
MDAndersonCancerCenterWebsite

Learn more about this trial

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

We'll reach out to this number within 24 hrs